Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 3
1983 4
1984 3
1985 5
1986 3
1987 8
1988 4
1989 4
1990 2
1991 2
1992 5
1993 8
1994 5
1995 6
1996 8
1997 6
1998 4
1999 10
2000 32
2001 19
2002 21
2003 17
2004 20
2005 33
2006 25
2007 50
2008 49
2009 73
2010 74
2011 74
2012 109
2013 100
2014 109
2015 116
2016 119
2017 114
2018 112
2019 118
2020 112
2021 101
2022 106
2023 117
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

1,716 results

Results by year

Filters applied: . Clear all
Page 1
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Chesney JA, et al. Among authors: shin sj. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. J Clin Oncol. 2023. PMID: 35998300 Free PMC article. Clinical Trial.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Antonarakis ES, et al. Among authors: shin sj. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8. J Clin Oncol. 2023. PMID: 37290035 Free PMC article. Clinical Trial.
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Nakamura Y, et al. Among authors: shin sj. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26. J Clin Oncol. 2023. PMID: 37751561 Free PMC article. Clinical Trial.
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Youn JW, et al. Among authors: shin sj. Lancet Oncol. 2020 Dec;21(12):1653-1660. doi: 10.1016/S1470-2045(20)30486-1. Lancet Oncol. 2020. PMID: 33271094 Clinical Trial.
A review of mucinous lesions of the breast.
Ginter PS, Tang X, Shin SJ. Ginter PS, et al. Among authors: shin sj. Breast J. 2020 Jun;26(6):1168-1178. doi: 10.1111/tbj.13878. Epub 2020 May 18. Breast J. 2020. PMID: 32419267 Review.
Inflammation promotes synucleinopathy propagation.
Kim TK, Bae EJ, Jung BC, Choi M, Shin SJ, Park SJ, Kim JT, Jung MK, Ulusoy A, Song MY, Lee JS, Lee HJ, Di Monte DA, Lee SJ. Kim TK, et al. Among authors: shin sj. Exp Mol Med. 2022 Dec;54(12):2148-2161. doi: 10.1038/s12276-022-00895-w. Epub 2022 Dec 6. Exp Mol Med. 2022. PMID: 36473937 Free PMC article.
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response.
Kim CG, Koh JY, Shin SJ, Shin JH, Hong M, Chung HC, Rha SY, Kim HS, Lee CK, Lee JH, Han Y, Kim H, Che X, Yun UJ, Kim H, Kim JH, Lee SY, Park SK, Park S, Kim H, Ahn JY, Jeung HC, Lee JS, Nam YD, Jung M. Kim CG, et al. Among authors: shin sj. Cell Rep Med. 2023 Nov 21;4(11):101251. doi: 10.1016/j.xcrm.2023.101251. Epub 2023 Oct 26. Cell Rep Med. 2023. PMID: 37890486 Free PMC article.
1,716 results